An EU-funded project developed a simple, affordable and effective vaccine strategy to prevent the incidence of both hepatitis C virus and HIV-1. This could significantly increase the life expectancy of people receiving antiretroviral therapy for HIV-1.
Do people living with HIV age more quickly, despite the fact that their infection is well controlled? Concerns have emerged in recent years, and an EU-funded study was launched to look into the matter by exploring links with age-related conditions, with a specific focus on cognitive impairment. No acceleration was observed.
The weakened immune system in people with HIV/AIDS makes them particularly vulnerable to fungal infections such as cryptococcal meningitis, which can be deadly. The medicine used to treat the condition is flucytosine, and EU-funded researchers have developed a new and more efficient way of producing it. This will cut production costs, making it more affordable for people in low-income countries.
